U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H17N4OS.Br
Molecular Weight 345.259
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of THIAMINE BROMIDE

SMILES

[Br-].CC1=C(CCO)SC=[N+]1CC2=CN=C(C)N=C2N

InChI

InChIKey=URCYCZPVXXIFSR-UHFFFAOYSA-M
InChI=1S/C12H17N4OS.BrH/c1-8-11(3-4-17)18-7-16(8)6-10-5-14-9(2)15-12(10)13;/h5,7,17H,3-4,6H2,1-2H3,(H2,13,14,15);1H/q+1;/p-1

HIDE SMILES / InChI

Molecular Formula C12H16N4OS
Molecular Weight 264.347
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula BrH
Molecular Weight 80.912
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Thiamine, also known as vitamin B1, plays a key role in the human metabolism. It is present in many dietary sources such as meats, eggs, fish, beans and peas, nuts, and whole grains. Upon administration thiamine is converted by thiamine pyrophosphokinase-1 (TPK1) to the active form, thiamine pyrophosphate, which serves as a cofactor for enzymes involved in the TCA cycle and the non-oxidative part of the pentose phosphate pathway. The lack of thiamine may cause the thiamine deficiency. The classical syndrome caused primarily by thiamine deficiency in humans is beriberi, however, symptoms of thiamine deficiency also include congestive heart failure, metabolic acidosis, confusion, ataxia and seizures. Thiamine is a component of many vitamin complexes, which are approved for the treatmen and prevention of general vitamin deficiency, including the thiamine deficiency.

CNS Activity

Curator's Comment: The transport of thiamine across the blood brain barrier was shown in rats.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q9H3S4
Gene ID: 27010.0
Gene Symbol: TPK1
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
M.V.I.-12

Approved Use

M.V.I.-12 Unit Vial, is indicated for the prevention of vitamin deficiency in adults and children aged 11 years and above who are on warfarin anticoagulant therapy receiving home parenteral nutrition.

Launch Date

1953
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
40 nM
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THIAMINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
39 nM
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THIAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
95 nM
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THIAMINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
113 nM
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THIAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
386 nM
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THIAMINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
397 nM
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THIAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
214 nM × h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THIAMINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
177 nM × h
100 mg single, oral
dose: 100 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THIAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
623 nM × h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THIAMINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
612 nM × h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THIAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2046 nM × h
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THIAMINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2059 nM × h
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THIAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.92 h
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THIAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
4.78 h
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THIAMINE blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
2.97 h
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
THIAMINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
Doses

Doses

DosePopulationAdverse events​
500 mg single, intravenous
Highest studied dose
Dose: 500 mg
Route: intravenous
Route: single
Dose: 500 mg
Sources:
unhealthy, adult
Health Status: unhealthy
Age Group: adult
Sex: unknown
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
The role of the cysteine residues of ThiI in the generation of 4-thiouridine in tRNA.
2001-09-07
Sulphoacetaldehyde sulpho-lyase (EC 4.4.1.12) from Desulfonispora thiosulfatigenes: purification, properties and primary sequence.
2001-07-15
No association between DLST gene and Alzheimer's disease or Wernicke-Korsakoff syndrome.
2001-07-11
Use of vitamin supplements and cataract: the Blue Mountains Eye Study.
2001-07
Low thiamine intake and risk of cataract.
2001-07
Nerve conduction changes in patients with mitochondrial diseases treated with dichloroacetate.
2001-07
Mechanism of thiamine uptake by human colonocytes: studies with cultured colonic epithelial cell line NCM460.
2001-07
Crystal structure of thiamin pyrophosphokinase.
2001-06-29
Painful alcoholic polyneuropathy with predominant small-fiber loss and normal thiamine status.
2001-06-26
Catalytic acid-base groups in yeast pyruvate decarboxylase. 1. Site-directed mutagenesis and steady-state kinetic studies on the enzyme with the D28A, H114F, H115F, and E477Q substitutions.
2001-06-26
Application of liquid chromatography to the simultaneous determination of acetylsalicylic acid, caffeine, codeine, paracetamol, pyridoxine, and thiamine in pharmaceutical preparations.
2001-06-22
Comparison of ion-pair and amide-based column reversed-phase liquid chromatography for the separation of thiamine-related compounds.
2001-06-15
[Metabolic characteristics of the Yarrowia lipolytica strain producing alpha-ketoglutaric and citric acids from ethanol and the effect of [NH4+] and [O2] on yeast respiration and biosynthesis].
2001-06-02
Chronic heart failure and micronutrients.
2001-06-01
The crystal structure of yeast thiamin pyrophosphokinase.
2001-06
Vitamin B intake and status in healthy Havanan men, 2 years after the Cuban neuropathy epidemic.
2001-06
Nutritional status in elderly female hip fracture patients: comparison with an age-matched home living group attending day centres.
2001-06
Sulfur compounds reduce potato toxins during extrusion cooking.
2001-06
Vitamin B1 and B6 retention in milk after continuous-flow microwave and conventional heating at high temperatures.
2001-06
Slc19a2: cloning and characterization of the murine thiamin transporter cDNA and genomic sequence, the orthologue of the human TRMA gene.
2001-06
Simultaneous determination of thiamine and pyridoxine in pharmaceuticals by using a single flow-through biparameter sensor.
2001-06
Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART.
2001-06
Thiamine-responsive megaloblastic anemia syndrome: a disorder of high-affinity thiamine transport.
2001-05-19
[Isolation, purification and properties of acetolactate synthase from cultured Lactococcus lactis].
2001-05-19
[Other drugs administered with TPN solution].
2001-05
[Metabolic acidosis induced by TPN].
2001-05
[Solutions for the hyperalimentation].
2001-05
The application of capillary electrophoresis to the analysis of vitamins in food and beverages.
2001-05
Pharmacotherapy of mental illness--a historical analysis.
2001-05
Biogenic amine metabolites and thiamine in cerebrospinal fluid in heredo-degenerative ataxias.
2001-05
A novel mutation in the SLC19A2 gene in a Tunisian family with thiamine-responsive megaloblastic anaemia, diabetes and deafness syndrome.
2001-05
Early recognition of acute cardiovascular beriberi by interpretation of hemodynamics.
2001-05
Wernicke's encephalopathy in a non-alcoholic man: case report and brief review.
2001-05
Stability of thiamine and vitamins E and A during storage of enteral feeding formula.
2001-05
[Chronic alcohol abuse. Benfotiamine in alcohol damage is a must].
2001-04-19
Rapid diagnosis of alcoholic ketoacidosis by proton NMR.
2001-04
Severe metabolic acidosis and heart failure due to thiamine deficiency.
2001-04
Do breastfed infants need supplemental vitamins?
2001-04
The genes for anabolic 2-oxoglutarate: ferredoxin oxidoreductase from Hydrogenobacter thermophilus TK-6.
2001-03-30
Relationships between dietary intake and cognitive function level in Korean elderly people.
2001-03
Wernicke's encephalopathy in patients with hyperemesis gravidarum.
2001-03
[Shoshin beriberi: myth or reality?].
2001-03
Reaction mechanism for mammalian pyruvate dehydrogenase using natural lipoyl domain substrates.
2001-02-15
Inhibitors of advanced glycation end product-associated protein cross-linking.
2001-02-14
The multifaceted and widespread pathology of magnesium deficiency.
2001-02
Molecular cloning of human thiamin pyrophosphokinase.
2001-01-26
Isolation and characterization of a human thiamine pyrophosphokinase cDNA.
2001-01-26
Thiamine for Alzheimer's disease.
2001
[Evaluation of vitamin and immune status of patients with chronic palatal tonsillitis].
2001
Effects of vitamins on hepatic nuclear binding of L-tryptophan.
2001
Patents

Sample Use Guides

The starting dose (as a component of M.V.I.–12) is one 10 mL daily dose added directly to an intravenous fluid.
Route of Administration: Intravenous
Human Caco-2 cells were incubated (37 Celsius) in Krebs-Ringer buffer (pH 7.4) for different periods of time in the presence of 0.1 uM and 10 uM thiamine. The uptake study demonstrated that thiamine is transported across the cell membrane with Michaelis-Menten constant of 3.18 uM.
Substance Class Chemical
Created
by admin
on Mon Mar 31 19:53:30 GMT 2025
Edited
by admin
on Mon Mar 31 19:53:30 GMT 2025
Record UNII
JIJ7B8T57F
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
THIAMINIUM BROMIDE
Preferred Name English
THIAMINE BROMIDE
WHO-DD  
Common Name English
Thiamine bromide [WHO-DD]
Common Name English
3-((4-AMINO-2-METHYL-5-PYRIMIDINYL)METHYL)-5-(2-HYDROXYETHYL)-4-METHYLTHIAZOLIUM BROMIDE
Systematic Name English
Code System Code Type Description
FDA UNII
JIJ7B8T57F
Created by admin on Mon Mar 31 19:53:30 GMT 2025 , Edited by admin on Mon Mar 31 19:53:30 GMT 2025
PRIMARY
CAS
7019-71-8
Created by admin on Mon Mar 31 19:53:30 GMT 2025 , Edited by admin on Mon Mar 31 19:53:30 GMT 2025
PRIMARY
EPA CompTox
DTXSID40990431
Created by admin on Mon Mar 31 19:53:30 GMT 2025 , Edited by admin on Mon Mar 31 19:53:30 GMT 2025
PRIMARY
PUBCHEM
71284
Created by admin on Mon Mar 31 19:53:30 GMT 2025 , Edited by admin on Mon Mar 31 19:53:30 GMT 2025
PRIMARY
MESH
C003434
Created by admin on Mon Mar 31 19:53:30 GMT 2025 , Edited by admin on Mon Mar 31 19:53:30 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY